



**World Health
Organization**

**World Health
Organization**

Annual Meeting of the Global Buruli Ulcer Initiative

**31 March to 2 April 2009
Cotonou, Benin**

Common and Control Sessions – Draft Agenda

Tuesday, 31 March (Common Session)

09:00 – 10:30: Country updates I

1. Benin (*Christian Johnson*)
2. Australia (*Paul Johnson*)
3. French Guiana (*Pierre Couppie*)
4. Togo (*Salomon Hainga*)
5. Cameroon (*Charles Nsom Mba, Earnest Njih*)

11:00 – 12:30 : Country updates II

1. Ghana (*Edwin Ampadu*)
2. Côte d'Ivoire (*Henri Asse*)
3. DRC (*Anatole Kibadi*)
4. Gabon (*Bayonne Manou*)
5. Congo (*Damas Obvala*)

14:00 – 15:30: Antibiotic treatment I

1. Impacts of dosing frequency of the combination rifampin-streptomycin on its Bactericidal and Sterilizing Activities Against *Mycobacterium ulcerans* in mice (*Baohong Ji*)
2. Comparison of rifapentine and rifampin based oral regimens in treatment of *Mycobacterium ulcerans* infection in mice (*Deepak Almeida*)
3. Serum neopterin during antibiotic treatment of Buruli ulcer disease; evidence of macrophage activation (*Steven Sarfo*)
4. Analysis of histopathological changes and local immune responses in the course of R/S chemotherapy in the experimental Buruli ulcer mouse model (*Marie-Thérèse Ruf*)
5. Severe multifocal form of Buruli ulcer after streptomycin and rifampicin treatment: a case report with comments on possible dissemination mechanisms (*Ange Dossou*)

16:00 – 17:30: Antibiotic treatment II

1. Preliminary results of a clinical trial of eight-week daily treatment with the combination rifampin-clarithromycin for patients with Buruli ulcer (*Annick Chauty & Baohing Ji*)
2. Prognostic indicators associated with the clinical response after 4 weeks of treatment of suspected Buruli ulcer cases with rifampicin and streptomycin in Allada, Benin
3. Response to treatment with combination rifampicin-streptomycin for 5 days per week for 8 weeks for Buruli ulcer (*Richard Phillips*)
4. Antimicrobial treatment for Buruli ulcer: the Burulico trial final results (*Tjip van der Werf*)
5. Patterns of healing and paradoxical reactions during antimicrobial treatment of Buruli ulcer – data from a drug trial in Ghana (*Willemien Nienhuis*)

Wednesday, 1 April (Control Session)

08:30 – 10:30: Laboratory confirmation of cases (10 minutes each)

1. The value of diagnosis of *M. ulcerans* infection by Fine Needle aspiration (*Viviane Cassisa*)
2. Confirmation of cases of Buruli ulcer at the National Buruli Ulcer Reference Laboratory (LNRUB) of the Institut National de Recherche Biomédicale (INRB-Kinshasa) in the Democratic Republic of the Congo (*Anatole Kibadi*)
3. Buruli ulcer molecular diagnosis routinely performed in Cotonou, Benin (*Dissou Affolabi*)
4. Confirmation of Buruli ulcer in Central African Republic (*Fanny Minime-Lingoupou*)
5. Overview and prospect for the National Buruli Ulcer Reference Centre (CNR-BURULI) in the Buruli ulcer control effort in Côte d'Ivoire (*N'Guetta Aka*)

10:30 – 12:30: NGOs

1. ANESVAD, Spain (*Almuneda Mendez Morante*)
2. Raoul Follereau Foundation, France (*Jacques Grosset*)
3. Raoul Follereau Foundation, Luxembourg (*Emile China*)
4. SCOBU, Japan (*Yuki Shimomura*)

14:00 – 15:30: Health system

1. Integration of Buruli ulcer control activities into primary health care: the case of the control programme of the Institut Médical Evangélique (IME)/Kimpese in the Democratic Republic of the Congo (DRC) (*B. B. Imposo*)
2. Decentralization (*Felix Sagno*)
3. Organization of case management for Buruli ulcer patients in Kouilou department in the Republic of the Congo (*Jean-Martin Mabiala*)
4. Three years of implementation of early detection activities in Amansie West District of Ghana (*Joseph Adomako*)
5. Early detection and management of Buruli ulcer in the Upper Denkyira district of Ghana (*Erasmus Klutse*)

16:00 – 17:30: Health system

1. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin (*Yves Barogui*)
2. Basic training in POD: Experience from Cameroon (*Valarie Simonet*)
3. Buruli ulcer in Togo: Prevention and treatment of disabilities from Buruli ulcer in the Maritime region (*Pauline Falipou*)
4. Wrist contractures following BU : the place of proximal row resection (*Patrick Meredith*)
5. Multicenter Surgical Outreach for Management of Buruli ulcer (*Pius Agbenorkou*)
6. Modern dressings (*Felix Sagno*)

Thursday, 2 April**09:00 – 10:30: Surveillance**

1. Analysis of the BU 01 in Benin for 2008–lessons learnt (*Yves Barogui*)
2. Mapping of Buruli ulcer cases in Benin shows highly focalized nature of the disease (*Ghislain Sopoh*)
3. Surveillance of Buruli ulcer in Ghana (*William Opare*)
4. Analysis of factors associated with seeking treatment among Buruli ulcer patients (*Alphonse Um Boock*)
5. Care and treatment given to patients and results obtained from the district of Akonolinga (*Francois Sihow*)
6. New foci of Buruli ulcer, Angola and Democratic Republic of Congo (*Anatole Kibadi*)

11:00 – 12:30: Other presentations

1. Cost of case management of Buruli ulcer cases at the Buruli ulcer Detection and Treatment Centre (CDTUB) at Allada in Benin (*Patrick Makoutode*)
2. Buruli ulcer: Perception of the disease and study of risk factors in endemic and non-endemic zones in Côte d'Ivoire (*Emmanuel Tia*)
3. Investigation of hematologic parameters in patients suspected of Buruli ulcer in two endemic areas in Benin (*Evelyne Lozes*)
4. Extra Cutaneous Manifestations Of Buruli Ulcer (*K. Kadjo*)
5. Yaws activities in Congo (*Damas Obvala*)

14 :00 – 15 :30 : Finalization of report

1. Preparations of control and research reports (*Chair and Rapporteurs*)
2. Group work to finalize a draft roadmap for implementation of the *Cotonou Declaration*

16:00 – 17:30: Closure

1. Plenary: presentation of conclusions and recommendations
2. Closing remarks: *TBA*